Medical Device Multiple Sclerosis Therapeutics Market Research | Page 2

REPORT DESCRIPTION
Multiple Sclerosis Therapeutics Market – Overview
The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary
progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing
neurological symptoms, PPMS is the rare form characterized by gradual progression of disease, whereas
SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms
of the disease include partial or complete vision loss, prolonged vision loss, lack of coordination, and
slurred speech.
A combination of genetic and environmental factors is responsible for the occurrence of the condition.
According to a study by International Progressive Alliance, 2013, MS is two to three times more common
in women than in men, suggesting that hormones play a significant role in determining susceptibility to the
disease.
The global multiple sclerosis therapeutics market was valued at US$ 19.6 billion in 2016 and is expected to
witness a robust CAGR of 2.5% over the forecast period (2017 – 2025).